Engineered hybrid carbon nanohorns-lipid platforms for the delivery of cisplatin to the colorectal cancer

Abstract

Carbon nanostructures are considered distinctive multi-functional drug delivery platforms for cancer therapy. However, their potential biocompatibility is still a significant challenge and rational design of these carriers is a prospect in the context of efficient cancer therapy. Herein, we report on the synthesis of two bio-inspired carbon nanohorns (CNH) platforms with tumor targeting capabilities for the delivery of cisplatin. Oxidized CNH wrapped with either polyethylene glycol (PEG) and fusogenic lipids (PEG/DSPG CNH-CP) or glutamic acid-cisplatin complex (CNH-GA-CP), revealed nanosized dahlia-like structure approved by dynamic light scattering (DLS) and transmission electron microscopy (TEM) analysis. Further structure features analysis by using RAMAN, FTIR spectroscopy and TGA indicated CNH surface modification. Excitingly, the superior nanofeatures of the CNH platforms was due to the reduced hydrophobic interactions, and thus closely linked to the surface modifications. Both platforms preserved cisplatin toxicity in vitro on C26 cells. The PEGylated nanoplatform demonstrated elongated circulation time compared to the free drug, and showed a site-specific delivery to the tumor site, while reducing the accumulation within kidney. Following 3 i.v. doses at 3 mg/kg of cisplatin, PEGylated CNH significantly delayed tumor growth and improved the life span of C26-bearing BALB/c mice. These notable results were further approved by the histopathological data, demonstrating reduced degeneration, necrosis and inflammation in both kidney and liver tissues following PEGylated nanoplatform administration. In conclusion, our findings suggest that the systemic toxicity of cisplatin including nephrotoxicity can be resolved by delivering this chemotherapeutic through a rationally-fabricated surface-modified carbon nanoplatform to improve the cancer therapy outcome.